High Growth Tech Stocks Featuring Three Prominent US Companies

Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences to Participate at Investor Conferences in November

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia

Neurocrine Biosciences Inc (NBIX) Q3 2024 Earnings Call Highlights: Strong Sales and Strategic ...

Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight

Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates

Neurocrine: Q3 Earnings Snapshot

Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance